Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes and interventions

Frontiers in Psychiatry

Volumn 5, Issue SEP, 2014, Pages

  Ringen, P Andreas ^a,b   Engh, John A ^c   Birkenaes, Astrid B ^d   Dieset, Ingrid ^a,b   Andreassen, Ole A ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c VESTFOLD HOSPITAL TRUST   (Norway)

^d Private practice ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; VARENICLINE; ZIPRASIDONE;

ARTICLE; BARIATRIC SURGERY; BEHAVIOR THERAPY; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GENETIC ASSOCIATION; HEALTH CARE DELIVERY; HEART ARRHYTHMIA; HELP SEEKING BEHAVIOR; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; KINESIOTHERAPY; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MEDLINE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT MONITORING; PHYSICAL INACTIVITY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SCHIZOPHRENIA; SECONDARY PREVENTION; SIDE EFFECT; SMOKING; SMOKING CESSATION; STANDARDIZED MORTALITY RATIO; SUBSTANCE ABUSE; SUDDEN CARDIAC DEATH; TARDIVE DYSKINESIA; TOBACCO DEPENDENCE; WEIGHT CONTROL; WEIGHT GAIN;

EID: 84907098498     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00137     Document Type: Article

References (193)

1. Agerbo,E., Byrne,M., Eaton,W.W. and Mortensen,P.B., 2004. MArital and labor market status in the long run in schizophrenia. Archives of General Psychiatry. 61, 28-33.
2. Allison,D.B. and Casey,D.E., 2001. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 62 Suppl 7, 22-31.
3. Allison,D.B., Newcomer,J.W., Dunn,A.L., Blumenthal,J.A., Fabricatore,A.N., Daumit,G.L., Cope,M.B., Riley,W.T., Vreeland,B., Hibbeln,J.R. and Alpert,J.E., 2009. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 36, 341-350.
4. Alstrõm,C.H., 1942. Mortality in mental hospitals with special regard to tuberculosis. Acta Psychiatrica and Neurologica Scandinavica. Suppl 4.
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity, 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 65, 267-272.
6. Amrami-Weizman,A., Maayan,R., Gil-Ad,I., Pashinian,A., Fuchs,C., Kotler,M. and Poyurovsky,M., 2013. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in people with schizophrenia. Psychopharmacology (Berl). 230, 23-27.
7. Andreassen,O.A., Djurovic,S., Thompson,W.K., Schork,A.J., Kendler,K.S., O'Donovan,M.C., Rujescu,D., Werge,T., van de Bunt,M., Morris,A.P., McCarthy,M.I., Roddey,J.C., McEvoy,L.K., Desikan,R.S. and Dale,A.M., 2013. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 92, 197-209.
8. Andreassen,O.A., McEvoy,L.K., Thompson,W.K., Wang,Y., Reppe,S., Schork,A.J., Zuber,V., Barrett-Connor,E., Gautvik,K., Aukrust,P., Karlsen,T.H., Djurovic,S., Desikan,R.S. and Dale,A.M., 2014. Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes. Hypertension. 63, 819-826.
9. Batel,P., 2000. Addiction and schizophrenia. Eur Psychiatry. 15, 115-122.
10. Beary,M., Hodgson,R. and Wildgust,H.J., 2012. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J Psychopharmacol. 26, 52-61.
11. Beebe,L.H. and Harris,R.F., 2013. Description of physical activity in outpatients withschizophrenia spectrum disorders. International Journal of Mental Health Nursing. 22, 430-436.
12. Beebe,L.H., Smith,K., Burk,R., McIntyre,K., Dessieux,O., Tavakoli,A., Tennison,C. and Velligan,D., 2011. Effect of a motivational intervention on exercise behavior in persons with schizophrenia spectrum disorders. Community Ment Health J. 47, 628-636.
13. Beebe,L.H., Tian,L., Goodwin,A., Morris,N., Swant-Allen,S. and Kuldau,J., 2005. Effects of exercise on the mental and physical health parameters of persons with schizophrenia. Issues in Mental Health Nursing. 26, 661-676.
14. Bennett,M.E., Wilson,A.L., Genderson,M. and Saperstein,A.M., 2013. Smoking Cessation in People with Schizophrenia. Curr Drug Abuse Rev. 6, 180-190.
15. Bickerstaff,L.K., Harris,S.C., Leggett,R.S. and Cheah,K.C., 1988. Pain insensitivity in schizophrenic patients. A surgical dilemma. Arch Surg. 123, 49-51.
16. Birkenaes,A.B., Birkeland,K.I., Engh,J.A., Faerden,A., Jonsdottir,H., Ringen,P.A., Friis,S., Opjordsmoen,S. and Andreassen,O.A., 2008. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 28, 132-137.
17. Birkenaes,A.B., Birkeland,K.I., Friis,S., Opjordsmoen,S. and Andreassen,O.A., 2009. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions. J Clin Psychopharmacol. 29, 109-116.
18. Birkenaes,A.B., Opjordsmoen,S., Brunborg,C., Engh,J.A., Jonsdottir,H., Ringen,P.A., Simonsen,C., Vaskinn,A., Birkeland,K.I., Friis,S., Sundet,K. and Andreassen,O.A., 2007. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 68, 917-923.
19. Blair,S.N., Kampert,J.B., Kohl,H.W., III, Barlow,C.E., Macera,C.A., Paffenbarger,R.S., Jr. and Gibbons,L.W., 1996. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 276, 205-210.
20. Blum,K., Braverman,E.R., Holder,J.M., Lubar,J.F., Monastra,V.J., Miller,D., Lubar,J.O., Chen,T.J. and Comings,D.E., 2000. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs. 32,1-112.
21. Bradford,D.W., Kim,M.M., Braxton,L.E., Marx,C.E., Butterfield,M. and Elbogen,E.B., 2008. Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv. 59, 847-852.
22. Bradley,A.J. and Dinan,T.G., 2010. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol. 24, 91-118.
23. Britt,E., Hudson,S.M. and Blampied,N.M., 2004. Motivational interviewing in health settings: a review. Patient Educ Couns. 53, 147-155.
24. Brown,S., 1997. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 171, 502-508.
25. Bueno,N.B., de Melo,I.S., de Oliveira,S.L. and da Rocha,A.T., 2013. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 110, 1178-1187.
26. Burghardt,K.J. and Ellingrod,V.L., 2013. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy: is there a role for folate? Mol Diagn Ther. 17, 21-30.
27. Bushe,C.J., Taylor,M. and Haukka,J., 2010. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol. 24, 17-25.
28. Callaghan,R.C., Veldhuizen,S., Jeysingh,T., Orlan,C., Graham,C., Kakouris,G., Remington,G. and Gatley,J., 2014. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res. 48, 102-110.
29. Casey,D.A., Rodriguez,M., Northcott,C., Vickar,G. and Shihabuddin,L., 2011. Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med. 41, 245-251.
30. CDC. Cigarette smoking among adults--United States, 2006. MMWR Morb Mortal Wkly Rep.2007. 56(44), 1157-1161. 9-11-2007. Centers for Disease Control and Prevention (CDC).
31. Chen,S., Broqueres-You,D., Yang,G., Wang,Z., Li,Y., Wang,N., Zhang,X., Yang,F. and Tan,Y., 2013. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res. 210, 825-829.
32. Chiuve,S.E., Fung,T.T., Rimm,E.B., Hu,F.B., McCullough,M.L., Wang,M., Stampfer,M.J. and Willett,W.C., 2012. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr. 142, 1009-1018.
33. Compton,M.T., Weiss,P.S., West,J.C. and Kaslow,N.J., 2005. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol. 40, 939-946.
34. Copeland,L.A., Zeber,J.E., Wang,C.P., Parchman,M.L., Lawrence,V.A., Valenstein,M. and Miller,A.L., 2009. Patterns of primary care and mortality among patients with schizophrenia or diabetes: a cluster analysis approach to the retrospective study of healthcare utilization. BMC Health Serv Res. 9, 127.
35. Corrado,E., Rizzo,M., Coppola,G., Fattouch,K., Novo,G., Marturana,I., Ferrara,F. and Novo,S., 2010. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 17, 1-11.
36. Crompton,D., Groves,A. and McGrath,J., 2010. What can we do to reduce the burden of avoidable deaths in those with serious mental illness? Epidemiol Psichiatr Soc. 19, 4-7.
37. Crump,C., Ioannidis,J.P., Sundquist,K., Winkleby,M.A. and Sundquist,J., 2013a. Mortality in persons with mental disorders is substantially overestimated using inpatient psychiatric diagnoses. J Psychiatr Res. 47, 1298-1303.
38. Crump,C., Sundquist,K., Winkleby,M.A. and Sundquist,J., 2013b. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 70, 931-939.
39. Darke,S., Kaye,S., McKetin,R. and Duflou,J., 2008. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 27, 253-262.
40. Das,C., Mendez,G., Jagasia,S. and Labbate,L.A., 2012. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry. 24, 225-239.
41. Daumit,G.L., Crum,R.M., Guallar,E. and Ford,D.E., 2002. Receipt of preventive medical services at psychiatric visits by patients with severe mental illness. Psychiatr Serv. 53, 884-887.
42. Daumit,G.L., Dalcin,A.T., Jerome,G.J., Young,D.R., Charleston,J., Crum,R.M., Anthony,C., Hayes,J.H., McCarron,P.B., Khaykin,E. and Appel,L.J., 2011. A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers. Int JObes (Lond). 35, 1114-1123.
43. De Hert,M., Correll,C.U. and Cohen,D., 2010. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res. 117, 68-74.
44. De Hert,M., Dekker,J.M., Wood,D., Kahl,K.G., Holt,R.I. and Moller,H.J., 2009. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 24, 412-424.
45. De Leon,J. and Diaz,F.J., 2005. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 76, 135-157.
46. De Leon,J., Susce,M.T., Johnson,M., Hardin,M., Pointer,L., Ruano,G., Windemuth,A. and Diaz,F.J., 2007. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 92, 95-102.
47. Dickerson,F., Stallings,C.R., Origoni,A.E., Vaughan,C., Khushalani,S., Schroeder,J. and Yolken,R.H., 2013. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv. 64, 44-50.
48. Dieset,I., Hope,S., Ueland,T., Bjella,T., Agartz,I., Melle,I., Aukrust,P., Rossberg,J.I. and Andreassen,O.A., 2012. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res. 140, 169-174.
49. Dipasquale,S., Pariante,C.M., Dazzan,P., Aguglia,E., McGuire,P. and Mondelli,V., 2013. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 47, 197-207.
50. Dodd,K.J., Duffy,S., Stewart,J.A., Impey,J. and Taylor,N., 2011. A small group aerobic exercise programme that reduces body weight is feasible in adults with severe chronic schizophrenia: a pilot study. Disabil Rehabil. 33, 1222-1229.
51. Emmons,K.M. and Rollnick,S., 2001. Motivational interviewing in health care settings. Opportunities and limitations. Am J Prev Med. 20, 68-74.
52. Engh,J.A., Friis,S., Birkenaes,A.B., Jonsdottir,H., Klungsoyr,O., Ringen,P.A., Simonsen,C., Vaskinn,A., Opjordsmoen,S. and Andreassen,O.A., 2010. Delusions are associated with poor cognitive insight in schizophrenia. Schizophr Bull. 36, 830-835.
53. Esposito,K., Kastorini,C.M., Panagiotakos,D.B. and Giugliano,D., 2013. Mediterranean diet and metabolic syndrome: an updated systematic review. Rev Endocr Metab Disord. 14, 255-263.
54. Faulkner,G., Cohn,T. and Remington,G., 2006. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Res. 82, 225-231.
55. Faulkner,G., Cohn,T. and Remington,G., 2007. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. CD005148.
56. Faulkner,G.E., Gorczynski,P.F. and Cohn,T.A., 2009. Psychiatric illness and obesity: recognizing the "obesogenic" nature of an inpatient psychiatric setting. Psychiatr Serv. 60, 538-541.
57. First,M.B. and Tasman,A., 2004. DSM-IV-TR Mental Disorders. Diagnosis, etiology and treatment. Wiley, Chichester.
58. Flier,J.S., 2004. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 116, 337-350.
59. Gaebel,W., Riesbeck,M. and Wobrock,T., 2011. Schizophrenia guidelines across the world: a selective review and comparison. Int Rev Psychiatry. 23, 379-387.
60. Ganguli,R., 2007. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry. 68 Suppl 4, 19-25.
61. Gerber,Y., Myers,V. and Goldbourt,U., 2012. Smoking reduction at midlife and lifetime mortality risk in men: a prospective cohort study. Am J Epidemiol. 175, 1006-1012.
62. Gloy,V.L., Briel,M., Bhatt,D.L., Kashyap,S.R., Schauer,P.R., Mingrone,G., Bucher,H.C. and Nordmann,A.J., 2013. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 347, f5934.
63. Gold,J.M., Waltz,J.A., Prentice,K.J., Morris,S.E. and Heerey,E.A., 2008. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull. 34, 835-847.
64. Gorczynski,P. and Faulkner,G., 2010. Exercise therapy for schizophrenia. Cochrane Database Syst Rev. CD004412.
65. Gorczynski,P., Faulkner,G., Greening,S. and Cohn,T., 2010. Exploring the construct validity of the transtheoretical model to structure physical activity interventions for individuals with serious mental illness. Psychiatr Rehabil J. 34, 61-64.
66. Green,M.F., 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 153, 321-330.
67. Hahn,B., Harvey,A.N., Concheiro-Guisan,M., Huestis,M.A., Holcomb,H.H. and Gold,J.M., 2013. A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry. 74, 436-443.
68. Hahn,M., Chintoh,A., Giacca,A., Xu,L., Lam,L., Mann,S., Fletcher,P., Guenette,M., Cohn,T., Wolever,T., Arenovich,T. and Remington,G., 2011. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res. 131, 90-95.
69. Hamoui,N., Kingsbury,S., Anthone,G.J. and Crookes,P.F., 2004. Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg. 14, 349-352.
70. Harris,L.W., Guest,P.C., Wayland,M.T., Umrania,Y., Krishnamurthy,D., Rahmoune,H. and Bahn,S., 2013. Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology. 38, 752-766.
71. Hart,C., Gruer,L. and Bauld,L., 2013. Does smoking reduction in midlife reduce mortality risk? Results of 2 long-term prospective cohort studies of men and women in Scotland. Am J Epidemiol. 178, 770-779.
72. Hartz,S.M., Pato,C.N. and Medeiros,H., 2014. COmorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 71, 248-254.
73. Hasan,A., Falkai,P., Wobrock,T., Lieberman,J., Glenthoj,B., Gattaz,W.F., Thibaut,F. and Moller,H.J., 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 14, 2-44.
74. Heggelund,J., Nilsberg,G.E., Hoff,J., Morken,G. and Helgerud,J., 2011. Effects of high aerobic intensity training in patients with schizophrenia: a controlled trial. Nord J Psychiatry. 65, 269-275.
75. Heiskanen,T., Niskanen,L., Lyytikainen,R., Saarinen,P.I. and Hintikka,J., 2003. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 64, 575-579.
76. Hennekens,C.H., Hennekens,A.R., Hollar,D. and Casey,D.E., 2005. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 150, 1115-1121.
77. Heymsfield,S.B., Greenberg,A.S., Fujioka,K., Dixon,R.M., Kushner,R., Hunt,T., Lubina,J.A., Patane,J., Self,B., Hunt,P. and McCamish,M., 1999. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 282, 1568-1575.
78. Hippisley-Cox,J., Parker,C., Coupland,C. and Vinogradova,Y., 2007. Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart. 93, 1256-1262.
79. Hooley,J.M. and Delgado,M.L., 2001. Pain insensitivity in the relatives of people with schizophrenia. Schizophr Res. 47, 265-273.
80. Hoye,A., Jacobsen,B.K. and Hansen,V., 2011. Increasing mortality in schizophrenia: are women at particular risk? A follow-up of 1111 patients admitted during 1980-2006 in Northern Norway. Schizophr Res. 132, 228-232.
81. Hu,F.B. and Willett,W.C., 2002. Optimal diets for prevention of coronary heart disease. JAMA. 288,2569-2578.
82. Jarvis,G.E., 2007. The social causes of psychosis in North American psychiatry: areviewof a disappearing literature. Can J Psychiatry. 52, 287-294.
83. Jin,H., Folsom,D., Sasaki,A., Mudaliar,S., Henry,R., Torres,M., Golshan,S., Glorioso,D.K. and Jeste,D., 2011. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res. 125, 295-299.
84. Johansson,K., Neovius,M. and Hemmingsson,E., 2014. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 99, 14-23.
85. Kapur,S., Mizrahi,R. and Li,M., 2005. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 79, 59-68.
86. Kaur,J., 2014. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract. 94,31-62.
87. Khan,A., Faucett,J., Morrison,S. and Brown,W.A., 2013. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attentiondeficit/ hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry. 70, 1091-1099.
88. Kilbourne,A.M., McCarthy,J.F., Welsh,D. and Blow,F., 2006. Recognition of co-occurring medical conditions among patients with serious mental illness. J Nerv Ment Dis. 194, 598-602.
89. Kim,S.F., Huang,A.S., Snowman,A.M., Teuscher,C. and Snyder,S.H., 2007. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 104, 3456-3459.
90. Kiviniemi,M., Suvisaari,J., Koivumaa-Honkanen,H., Hakkinen,U., Isohanni,M. and Hakko,H., 2013. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res. 150, 274-280.
91. Kodama,S., Saito,K., Tanaka,S., Maki,M., Yachi,Y., Asumi,M., Sugawara,A., Totsuka,K., Shimano,H., Ohashi,Y., Yamada,N. and Sone,H., 2009. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 301, 2024-2035.
92. Koola,M.M., McMahon,R.P., Wehring,H.J., Liu,F., Mackowick,K.M., Warren,K.R., Feldman,S., Shim,J.C., Love,R.C. and Kelly,D.L., 2012. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychiatr Res. 46, 987-993.
93. Korner,J., Conroy,R., Febres,G., McMahon,D.J., Conwell,I., Karmally,W. and Aronne,L.J., 2013. Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. Obesity (Silver Spring). 21, 951-956.
94. Kroeze,W.K., Hufeisen,S.J., Popadak,B.A., Renock,S.M., Steinberg,S., Ernsberger,P., Jayathilake,K., Meltzer,H.Y. and Roth,B.L., 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 28, 519-526.
95. Laursen,T.M., Munk-Olsen,T. and Vestergaard,M., 2012. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 25, 83-88.
96. Laursen,T.M., Nordentoft,M. and Mortensen,P.B., 2013a. Excess Early Mortality in Schizophrenia. Annu Rev Clin Psychol. 425-448.
97. Laursen,T.M., Wahlbeck,K., Hallgren,J., Westman,J., Osby,U., Alinaghizadeh,H., Gissler,M. and Nordentoft,M., 2013b. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 8, e67133.
98. Lavie,C.J., Thomas,R.J., Squires,R.W., Allison,T.G. and Milani,R.V., 2009. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc. 84, 373-383.
99. Lawrence,D., Mitrou,F. and Zubrick,S.R., 2009. Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health. 9, 285.
100. Lee,M.H. and Hancox,R.J., 2011. Effects of smoking cannabis on lung function. Expert Rev Respir Med. 5, 537-546.
101. Lee,S.J., Choi,E.J. and Kwon,J.S., 2008. A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 69, 555-562.
102. Leonard,B.E., Schwarz,M. and Myint,A.M., 2012. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol. 26, 33-41.
103. Leucht,S., Burkard,T., Henderson,J., Maj,M. and Sartorius,N., 2007. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 116, 317-333.
104. Levensky,E.R., Forcehimes,A., O'Donohue,W.T. and Beitz,K., 2007. Motivational interviewing: an evidence-based approach to counseling helps patients follow treatment recommendations. Am J Nurs. 107, 50-58.
105. Lottenberg,A.M., Afonso,M.S., Lavrador,M.S., Machado,R.M. and Nakandakare,E.R., 2012. The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem. 23, 1027-1040.
106. Maayan,L., Vakhrusheva,J. and Correll,C.U., 2010. Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. 35, 1520-1530.
107. Mann,J.I., 2006. Nutrition recommendations for the treatment and prevention of type 2 diabetes and the metabolic syndrome: an evidenced-based review. Nutr Rev. 64, 422-427.
108. Manu,P., Kane,J.M. and Correll,C.U., 2011. Sudden deaths in psychiatric patients. J Clin Psychiatry. 72, 936-941.
109. Marchand,W.E., 1955. Occurrence of painless myocardial infarction in psychotic patients. N Engl J Med. 253, 51-55.
110. Maudsley,H., 1879. The Pathology of Mind, 3 edn. Macmillan, London, p. 113.
111. McEvoy,J.P., Meyer,J.M., Goff,D.C., Nasrallah,H.A., Davis,S.M., Sullivan,L., Meltzer,H.Y., Hsiao,J., Scott,S.T. and Lieberman,J.A., 2005. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 80, 19-32.
112. McGrath,J., Saha,S., Chant,D. and Welham,J., 2008. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol Rev. 30, 67-76.
113. McLeod,H.J., Jaques,S. and Deane,F.P., 2009. Base rates of physical activity in Australians with schizophrenia. Psychiatr Rehabil J. 32, 269-275.
114. Meduna,L.J., Gerty,F.J. and Urse,V.G., 1942. Biochemical disturbances in mental disorders. Arch Neurol Psychiatry. 38-52.
115. Melamed,Y., Stein-Reisner,O., Gelkopf,M., Levi,G., Sivan,T., Ilievici,G., Rosenberg,R., Weizman,A. and Bleich,A., 2008. Multi-modal weight control intervention for people with persistent mental disorders. Psychiatr Rehabil J. 31, 194-200.
116. Mennella,J.A., 2014. Ontogeny of taste preferences: basic biology and implications for health. Am J Clin Nutr. 99, 704S-711S.
117. Menza,M., Vreeland,B., Minsky,S., Gara,M., Radler,D.R. and Sakowitz,M., 2004. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 65, 471-477.
118. Methapatara,W. and Srisurapanont,M., 2011. Pedometer walking plus motivational interviewing program for Thai schizophrenic patients with obesity or overweight: a 12-week, randomized, controlled trial. Psychiatry Clin Neurosci. 65, 374-380.
119. Miller,B.J., Buckley,P., Seabolt,W., Mellor,A. and Kirkpatrick,B., 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 70, 663-671.
120. Miller,W.R. and Rollnick,S., 2009. Ten things that motivational interviewing is not. Behav Cogn Psychother. 37, 129-140.
121. Miron,I.C., Baroana,V.C., Popescu,F. and Ionica,F., 2014. Pharmacological Mechanisms Underlying the Association of Antipsychotics with Metabolic Disorders. Curr Health Sci J. 40, 12-17.
122. Mitchell,A.J., Delaffon,V., Vancampfort,D., Correll,C.U. and De,H.M., 2012a. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 42, 125-147.
123. Mitchell,A.J. and Lord,O., 2010. Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. J Psychopharmacol. 24, 69-80.
124. Mitchell,A.J., Lord,O. and Malone,D., 2012b. Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. Br J Psychiatry. 201, 435-443.
125. Mitchell,A.J., Vancampfort,D., De,H.A., Yu,W. and De,H.M., 2013. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative metaanalysis of first episode, untreated and treated patients. Schizophr Bull. 39, 295-305.
126. Mizuno,Y., Suzuki,T., Nakagawa,A., Yoshida,K., Mimura,M., Fleischhacker,W.W. and Uchida,H. Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 17-3-2014. 20-6-2014.
127. Mondelli,V., Cattaneo,A., Belvederi,M.M., Di,F.M., Handley,R., Hepgul,N., Miorelli,A., Navari,S., Papadopoulos,A.S., Aitchison,K.J., Morgan,C., Murray,R.M., Dazzan,P. and Pariante,C.M., 2011. Stress and inflammation reduce brain-derived neurotrophic factor expression in firstepisode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry. 72, 1677-1684.
128. Moos,R.H., Brennan,P.L. and Mertens,J.R., 1994. Mortality rates and predictors of mortality among late-middle-aged and older substance abuse patients. Alcohol Clin Exp Res. 18, 187-195.
129. Morrato,E.H., Newcomer,J.W., Kamat,S., Baser,O., Harnett,J. and Cuffel,B., 2009. Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes. Diabetes Care. 32, 1037-1042.
130. Mueser,K.T. and McGurk,S.R., 2004. Schizophrenia. Lancet. 363, 2063-2072.
131. Nasrallah,H.A., 2006. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr. 11, 32-39.
132. Nawrot,T.S., Perez,L., Kunzli,N., Munters,E. and Nemery,B., 2011. Public health importance of triggers of myocardial infarction: a comparative risk assessment. Lancet. 377, 732-740.
133. NICE. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. [March 2009]. 3-8-2011. The National Institute for Health and Clinical Excellence.
134. Niskanen,L.K., Hintikka,J.J., Koivumaa-Honkanen,H.T., Honkalampi,K.M., Haatainen,K.M. and Viinama¨ki,H.-T., 2006. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry. 67, 1422-1427.
135. Nordentoft,M., Wahlbeck,K., Hallgren,J., Westman,J., Osby,U., Alinaghizadeh,H., Gissler,M. and Laursen,T.M., 2013. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 8, e55176.
136. Odegard,O., 1951. Mortality in Norwegian mental hospitals 1926-1941. Acta Genet Stat Med. 2, 141-173.
137. Osborn,D.P., Levy,G., Nazareth,I., Petersen,I., Islam,A. and King,M.B., 2007. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 64, 242-249.
138. Osby,U., Correia,N., Brandt,L., Ekbom,A. and Sparen,P., 2000. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 45, 21-28.
139. Pagels,P., Raustorp,A., Archer,T., Lidman,U. and Alricsson,M., 2011. Influence of Moderate, Daily Physical Activity Upon Body Composition and Blood Lipid Profile in Swedish Adults. J Phys Act Health. 9, 867-874.
140. Perez-Iglesias,R., Crespo-Facorro,B., Martinez-Garcia,O., Ramirez-Bonilla,M.L., Alvarez-Jimenez,M., Pelayo-Teran,J.M., Garcia-Unzueta,M.T., Amado,J.A. and Vazquez-Barquero,J.L., 2008. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res. 99, 13-22.
141. Perez-Iglesias,R., Martinez-Garcia,O., Pardo-Garcia,G., Amado,J.A., Garcia-Unzueta,M.T., Tabares-Seisdedos,R. and Crespo-Facorro,B., 2014. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol. 17, 41-51.
142. Petersen,L. and Sorensen,T.I., 2011. Studies based on the Danish Adoption Register: schizophrenia, BMI, smoking, and mortality in perspective. Scand J Public Health. 39, 191-195.
143. Planansky,K., 1958. Changes in weight in patients receiving a tranquilizing drug. Psychiatr Q. 32,289-303.
144. Porsdal,V., Beal,C., Kleivenes,O.K., Martinsen,E.W., Lindstrom,E., Nilsson,H. and Svanborg,P., 2010. The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. BMC Psychiatry. 10, 42.
145. Potvin,S. and Marchand,S., 2008. Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a systematic quantitative review of experimental studies. Pain. 138, 70-78.
146. Potvin,S., Stip,E., Sepehry,A.A., Gendron,A., Bah,R. and Kouassi,E., 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 63, 801-808.
147. Powers,P.S. and Cloak,N.L., 2012. Psychopharmacologic treatment of obesity and eating disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am. 21, 831-859.
148. Ragg,M., Gordon,R., Ahmed,T. and Allan,J., 2013. The impact of smoking cessation on schizophrenia and major depression. Australas Psychiatry. 21, 238-245.
149. Raphael,T.P. and Parsons,J.P., 1921. Blood sugar studies in dementia praecox and manic depressive insanity. Arch Neurol Psychiatry. 5, 687-709.
150. Rasanen,S., Hakko,H., Viilo,K., Meyer-Rochow,V.B. and Moring,J., 2003. Excess mortality among long-stay psychiatric patients in Northern Finland. Soc Psychiatry Psychiatr Epidemiol. 38,297-304.
151. Ray,W.A., Chung,C.P., Murray,K.T., Hall,K. and Stein,C.M., 2009. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 360, 225-235.
152. Reilly,J.G., Ayis,S.A., Ferrier,I.N., Jones,S.J. and Thomas,S.H., 2002. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry. 180, 515-522.
153. Ringen,P.A., Melle,I., Birkenaes,A.B., Engh,J.A., Faerden,A., Jonsdottir,H., Nesvag,R., Vaskinn,A., Friis,S., Larsen,F., Opjordsmoen,S., Sundet,K. and Andreassen,O.A., 2008a. Illicit drug use in patients with psychotic disorders compared with that in the general population: a crosssectional study. Acta Psychiatr Scand. 117, 133-138.
154. Ringen,P.A., Melle,I., Birkenaes,A.B., Engh,J.A., Faerden,A., Vaskinn,A., Friis,S., Opjordsmoen,S. and Andreassen,O.A., 2008b. The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatr Scand. 297-304.
155. Roberts,L., Roalfe,A., Wilson,S. and Lester,H., 2007. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract. 24, 34-40.
156. Roberts,S.H. and Bailey,J.E., 2011. Incentives and barriers to lifestyle interventions for people with severe mental illness: a narrative synthesis of quantitative, qualitative and mixed methods studies. J Adv Nurs. 67, 690-708.
157. Roick,C., Fritz-Wieacker,A.F., Matschinger,H., Riedel-Heller,S. and Fru¨hwald,S., 2007. Health habits of patients with schizophrenia: a general pattern? Soc Psychiatry Psychiatr Epidemiol. 42, 268-276.
158. Rosenthal,S.H., Porter,K.A. and Coffey,B., 1990. Pain insensitivity in schizophrenia. Case report and review of the literature. Gen Hosp Psychiatry. 12, 319-322.
159. Rossler,W., Salize,H.J., Van,O.J. and Riecher-Rossler,A., 2005. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 15, 399-409.
160. Rummel-Kluge,C., Komossa,K., Schwarz,S., Hunger,H., Schmid,F., Lobos,C.A., Kissling,W., Davis,J.M. and Leucht,S., 2010. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 123, 225-233.
161. Ryan,M.C., Collins,P. and Thakore,J.H., 2003. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 160, 284-289.
162. Saari,K.M., Lindeman,S.M., Viilo,K.M., Isohanni,M.K., Jarvelin,M.R., Lauren,L.H., Savolainen,M.J. and Koponen,H.J., 2005. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry. 66, 559-563.
163. Saha,S., Chant,D. and McGrath,J., 2007. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 64, 1123-1131.
164. Saha,S., Whiteford,H. and McGrath,J., 2014. Modelling the incidence and mortality of psychotic disorders: data from the second Australian national survey of psychosis. Aust N Z J Psychiatry. 48, 352-359.
165. Salsberry,P.J., Chipps,E. and Kennedy,C., 2005. Use of general medical services among Medicaid patients with severe and persistent mental illness. Psychiatr Serv. 56, 458-462.
166. Scheewe,T.W., Backx,F.J., Takken,T., Jorg,F., van Strater,A.C., Kroes,A.G., Kahn,R.S. and Cahn,W., 2013. Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial. Acta Psychiatr Scand. 127, 464-473.
167. Schwingshackl,L. and Hoffmann,G., 2014. Comparison of the long-term effects of high-fat v. low-fat diet consumption on cardiometabolic risk factors in subjects with abnormal glucose metabolism: a systematic review and meta-analysis. Br J Nutr. 111, 2047-2058.
168. Smith,R.C., Lindenmayer,J.P., Bark,N., Warner-Cohen,J., Vaidhyanathaswamy,S. and Khandat,A., 2005. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol. 8, 183-194.
169. Smith,S.M., Meyer,M. and Trinkley,K.E., 2013. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 47, 340-349.
170. Straus,S.M., Bleumink,G.S., Dieleman,J.P., van der Lei,J., 't Jong,G.W., Kingma,J.H., Sturkenboom,M.C. and Stricker,B.H., 2004. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 164, 1293-1297.
171. Stunes,A.K., Reseland,J.E., Hauso,O., Kidd,M., Tommeras,K., Waldum,H.L., Syversen,U. and Gustafsson,B.I., 2011. Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation. Diabetes Obes Metab. 13, 551-558.
172. Suvisaari,J., Partti,K., Perñlñ,J., ViertiAˆ,S., Saarni,S.E., Laˆnnqvist,J., Saarni,S.I. and Hñrkñnen,T., 2013. Mortality and Its Determinants in People With Psychotic Disorder. Psychosomatic Medicine. 75.
173. Sweeting,J., Duflou,J. and Semsarian,C., 2013. Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophr Res. 150, 398-403.
174. Taylor,V., McKinnon,M.C., MacDonald,K., Jaswal,G. and MacQueen,G.M., 2010. Adults with mood disorders have an increased risk profile for cardiovascular disease within the first 2 years of treatment. Can J Psychiatry. 55, 362-368.
175. Tek,C., Guloksuz,S., Srihari,V.H. and Reutenauer,E.L., 2013. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry. 13, 176.
176. Thompson,D.R., Chair,S.Y., Chan,S.W., Astin,F., Davidson,P.M. and Ski,C.F., 2011. Motivational interviewing: a useful approach to improving cardiovascular health? J Clin Nurs. 20, 1236-1244.
177. Tiihonen,J., Lonnqvist,J., Wahlbeck,K., Klaukka,T., Niskanen,L., Tanskanen,A. and Haukka,J., 2009. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 374, 620-627.
178. Townsend,N., Bhatnagar,P., Wickramashinge,K., Scarborough,P., Foster,C. and Rayner,M. Physical Activity Statistics 2012. 2012. British Heart Foundation.
179. Tran,E., Rouillon,F., Loze,J.Y., Casadebaig,F., Philippe,A., Vitry,F. and Limosin,F., 2009. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer. 115,3555-3562.
180. Tsoi,D.T., Porwal,M. and Webster,A.C., 2013. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2, CD007253.
181. Vancampfort,D., Knapen,J., Probst,M., Scheewe,T., Remans,S. and De,H.M., 2011a. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 125, 352-362.
182. Vancampfort,D., Probst,M., Scheewe,T., Maurissen,K., Sweers,K., Knapen,J. and De Hert,M., 2011b. Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia. Schizophr Res. 129, 122-127.
183. Vestri,H.S., Maianu,L., Moellering,D.R. and Garvey,W.T., 2007. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology. 32, 765-772.
184. Vik-Mo,A.O., Birkenaes,A.B., Ferno,J., Jonsdottir,H., Andreassen,O.A. and Steen,V.M., 2008. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol. 11, 679-684.
185. Vincenzi,B., Borba,C.P., Gray,D.A., Copeland,P.M., Wang,X., Fan,X., Aragam,G.G. and Henderson,D.C., 2013. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in people with schizophrenia treated with atypical antipsychotics. Ann Clin Psychiatry 25, 141-148.
186. Volkow,N.D., Wang,G.J. and Baler,R.D., 2011. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci. 15, 37-46.
187. Vreeland,B., 2007. Bridging the gap between mental and physical health: a multidisciplinary approach. J Clin Psychiatry. 68 Suppl 4, 26-33.
188. Wang,J. and Li,M.D., 2010. Common and Unique Biological Pathways Associated with Smoking Initiation/Progression, Nicotine Dependence, and Smoking Cessation. Neuropsychopharmacology. 35, 702-719.
189. Weinmann,S., Read,J. and Aderhold,V., 2009. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 113, 1-11.
190. WHO. Global health risks: mortality and burden of disease attributable to selected major risks. WHO (2009). 2009. Geneva, World Health Organization.
191. Wildgust,H.J. and Beary,M., 2010. Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacol. 24, 37-50.
192. Wylie,K.P. and Tregellas,J.R., 2010. The role of the insula in schizophrenia. Schizophr Res. 123, 93-104.
193. Yanovski,S.Z. and Yanovski,J.A., 2014. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 311, 74-86.